Related Experiment Video
Updated: May 7, 2025
08:21
Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery
Published on: June 28, 2019
6.8K
Small-molecule modulation of β-arrestins.
Biorxiv : the Preprint Server for Biology
|January 7, 2025
Summary
Researchers developed novel small molecules that inhibit beta-arrestins (βarrs), crucial for G protein-coupled receptor (GPCR) signaling. These inhibitors block βarr interaction with GPCRs, offering new tools to study cellular processes.
Area of Science:
- Biochemistry
- Pharmacology
- Structural Biology
Background:
- Beta-arrestins (βarrs) are critical regulators of G protein-coupled receptors (GPCRs), influencing diverse physiological processes.
- Current drug discovery lacks specific tools to target βarrs, unlike GPCRs or G proteins.
Purpose of the Study:
- To discover and characterize novel small-molecule allosteric inhibitors of βarrs.
- To elucidate the mechanism of action and structural basis of βarr inhibition.
Main Methods:
- Biophysical, biochemical, and pharmacological assays.
- Cryo-electron microscopy (cryo-EM) for structural determination.
- Molecular dynamics (MD) simulations and mutagenesis studies.
Main Results:
- Identification of small molecules that disrupt βarr-GPCR interactions, impairing receptor internalization and desensitization.
- Cryo-EM structure of βarr1 complexed with inhibitor Cmpd-5 revealed binding in a cryptic cleft, acting as a molecular lock.
- Inhibitor binding induces a unique βarr1 conformation, elucidating the allosteric inhibition mechanism.
Conclusions:
- Novel small-molecule allosteric inhibitors of βarrs have been developed.
- These inhibitors provide new pharmacological tools for studying βarr functions in GPCR-dependent and independent pathways.
- The structural insights into Cmpd-5 binding offer a foundation for designing future βarr-targeted therapeutics.
More Related Videos
09:03Parallel Interrogation of β-Arrestin2 Recruitment for Ligand Screening on a GPCR-Wide Scale using PRESTO-Tango Assay
Published on: March 10, 2020
11.9K
07:16Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
Published on: August 16, 2018
13.5K
Related Concept Videos
01:30Ligand-Gated Ion Channel Receptor: Gating Mechanism
2.0K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
2.0K
01:17Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
738
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
738
01:25Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
440
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
440
01:12GPCR Desensitization
5.6K
G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
5.6K
01:30Assembly of Signaling Complexes
5.6K
Multiprotein signaling complexes are formed in a dynamic process involving protein-protein interactions at the cytoplasmic domain of transmembrane receptors or enzymatic and non-enzymatic proteins associated with the receptor. These complexes ensure the activation and propagation of intracellular signals that regulate cell functions.
Interaction domains in cell signaling
Interaction domains recognize exposed features of their binding partners containing post-translationally modified sequences,...
Interaction domains in cell signaling
Interaction domains recognize exposed features of their binding partners containing post-translationally modified sequences,...
5.6K
01:26Adrenergic Receptors: β Subtype
1.4K
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
1.4K